Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.

January 28, 2015

AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer’s Dementia

Phase 3-ready AGB101 designed to address aMCI, the pre-dementia stage of Alzheimer’s disease BALTIMORE, MD January 28, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia stage…

January 7, 2015

AgeneBio CEO Jerry McLaughlin to Present at Biotech Showcase 2015

BALTIMORE, MD January 7, 2015 /PR Newswire/ — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling amnestic mild cognitive impairment (aMCI), the pre-dementia phase of Alzheimer’s disease, and other neurological and psychiatric diseases, today announced that the…

November 18, 2014

AgeneBio Founder and Chief Scientific Officer Receives Society for Neuroscience’s Mika Salpeter Lifetime Achievement Award

BALTIMORE, MARYLAND—AgeneBio, a pharmaceutical company developing innovative therapeutics that prevent neurodegeneration and preserve and restore brain function, today announced that the Company’s founder and chief scientific officer Michela Gallagher, PhD, has received the Society for Neuroscience’s Mika Salpeter Lifetime Achievement…

July 22, 2014

AgeneBio Appoints Industry Leaders Patrick LePore as Chairman of the Board and Jerry McLaughlin as President and Chief Executive Officer

BALTIMORE, MARYLAND—AgeneBio, Inc., a clinical-stage pharmaceutical company developing medicines to restore and preserve patients’ cognitive function for a range of debilitating neurodegenerative diseases, today announced the appointment of Patrick LePore as chairman of the board and Jerry McLaughlin as president…